Subtype
Renal Cell Carcinoma
CI-CAN-00006578RCCExplore in graph →
375 active trials17 approved drugs60 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006578RCCExplore in graph →
Clinical trials
1,621 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (276)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01582009 | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | terminated | Phase 1 / Phase 2 | 26 | Roswell Park Cancer InstituteOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 |
| clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT03138538 | M8891 First in Human in Solid Tumors(M8891) | terminated | Phase 1 | 27 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | terminated | Phase 1 | 2 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT00324740 | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer | terminated | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT02495103 | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | terminated | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2020 | clinicaltrials |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 173 | Tracon Pharmaceuticals Inc.INDUSTRY | 4 | Oct 19, 2020 | clinicaltrials |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | terminated | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 16, 2020 | clinicaltrials |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer | terminated | Phase 1 / Phase 2 | 24 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | terminated | Phase 1 | 16 | Celldex TherapeuticsINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 16 | CelgeneINDUSTRY | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | terminated | Phase 1 | 6 | Virginia Commonwealth UniversityOTHER | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | terminated | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | terminated | Phase 1 | 17 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | terminated | Phase 1 | 26 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma(5-AZ) | terminated | Phase 1 / Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01943188 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer | terminated | Phase 1 | 2 | Stanford UniversityOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00672178 | Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) | terminated | Phase 1 / Phase 2 | 1 | Duke UniversityOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT02410174 | To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors | terminated | Phase 1 | 3 | Beth Israel Medical CenterOTHER | 1 | Jan 9, 2017 | clinicaltrials |
| NCT01144169 | Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | terminated | Phase 1 | 7 | University of PittsburghOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT00522249 | Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | terminated | Phase 1 / Phase 2 | 10 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00622479 | Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. | terminated | Phase 1 | 12 | BayerINDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01677390 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma | terminated | Phase 1 | 4 | Seagen Inc.INDUSTRY | 1 | Jan 28, 2014 | clinicaltrials |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00816686 | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer | terminated | Phase 1 | 7 | Astellas Pharma IncINDUSTRY | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 124 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Aug 15, 2022source: clinicaltrials